期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 111, 期 26, 页码 E2721-E2730出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1406722111
关键词
mouse models; JQ1; vorinostat; Brd2; Brd4
资金
- Swedish Cancer Society
- Swedish Research Council
- Sahlgrenska Academy
- BioCARE, a National Strategic Cancer Research Program at University of Gothenburg
- Deutsche Forschungsgemeinschaft
- Jose Carreras Leukamie Stiftung
- Deutsches Konsortium fur translationale Krebsforschung
- Assar Gabrielsson Foundation
- Lundgrenska stiftelserna
- Region Vastra Gotaland (Sahlgrenska University Hospital, Gothenburg)
The bromodomain and extraterminal (BET) domain family of proteins binds to acetylated lysines on histones and regulates gene transcription. Recently, BET inhibitors (BETi) have been developed that show promise as potent anticancer drugs against various solid and hematological malignancies. Here we show that the structurally novel and orally bioavailable BET inhibitor RVX2135 inhibits proliferation and induces apoptosis of lymphoma cells arising in Myc-transgenic mice in vitro and in vivo. We find that BET inhibition exhibits broad transcriptional effects in Myc-transgenic lymphoma cells affecting many transcription factor networks. By examining the genes induced by BETi, which have largely been ignored to date, we discovered that these were similar to those induced by histone deacetylase inhibitors (HDACi). HDACi also induced cell-cycle arrest and cell death of Myc-induced murine lymphoma cells and synergized with BETi. Our data suggest that BETi sensitize Myc-overexpressing lymphoma cells partly by inducing HDAC-silenced genes, and suggest synergistic and therapeutic combinations by targeting the genetic link between BETi and HDACi.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据